WO1996035447A1 - Pharmaceutical administration form of parathyroid hormone having an active ingredient release period of from two to six hours - Google Patents

Pharmaceutical administration form of parathyroid hormone having an active ingredient release period of from two to six hours Download PDF

Info

Publication number
WO1996035447A1
WO1996035447A1 PCT/EP1996/001962 EP9601962W WO9635447A1 WO 1996035447 A1 WO1996035447 A1 WO 1996035447A1 EP 9601962 W EP9601962 W EP 9601962W WO 9635447 A1 WO9635447 A1 WO 9635447A1
Authority
WO
WIPO (PCT)
Prior art keywords
hours
parathyroid hormone
administration form
active ingredient
quart
Prior art date
Application number
PCT/EP1996/001962
Other languages
French (fr)
Inventor
Peter-Paul Ochlich
Bernd MÜLLER-BECKMANN
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Priority to EP96919738A priority Critical patent/EP0825872A1/en
Priority to AU58165/96A priority patent/AU5816596A/en
Priority to JP8533762A priority patent/JPH11505222A/en
Publication of WO1996035447A1 publication Critical patent/WO1996035447A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention is directed to a pharmaceutical administration form of parathyroid hormone or parathyroid hormone derivatives having an active ingredient release period of from two to six hours, the use of parathyroid hormone in the treatment of osteoporosis by applying said pharmaceutical administration form, and a method for the treatment of osteoporosis in the human body.
  • Parathyroid hormone and N-terminal parathyroid hormone fragments are known to have osteogenous activity which has been observed in animal experimental studies on rats as well as in clinical studies on osteoporotic patients and has been described in technical literature (Selye, Endocrinology 16 (1932), 547-558; Hefti et al., Clin. Sci. 62 (1982), 389-396; Gunnes-Hey et al., Metab. Bone Dis. Relat. Res. 5 (1984), 177-181; Reeve et al., Br. Med. J. 280 (1980), 1340-1344; Slovik et al., J. Bone Miner. Res. 1 (1986), 377- 381, EP 0,197,514).
  • the invention is directed to a pharmaceutical administration form of PTH or derivatives thereof having an active ingredient release period of from two to six hours, and preferably of four hours.
  • the pharmaceutical administration form may be an infusion solution or a transdermic or enteric pharmaceutical system having an active ingredient release period of up to six hours.
  • the transdermic or enteric application of PTH offers the decisive advantage of retarded active ingredient release. Abrupt PTH pulses and the associated substantial disturbance of the patient's well-being due to the necessary injection can be dismissed.
  • the pharmaceutical administration form contains biologically active parathyroid hormone or parathyroid hormone derivatives, particularly human PTH(l-84) or an N-terminal human PTH fragment having the sequences 1-29 to
  • PT ⁇ - analogous peptides, variants or modifications of parathyroid hormone (PTH agonists) resulting from the replacement of single or multiple amino acids in the amino acid se ⁇ quence of unmodified parathyroid hormone may also be employed.
  • PTH fragments appropriately abridged at the N terminus and/or the C terminus are also possible within the meaning of the invention. Such fragments have been described in WO 90/10067, EP 0,301,484 or EP 0,301,485, for example.
  • PTH peptides are effected in such a manner that release of the pharmacologically active substance in the body within a period of from 2 to 6 hours is ensured. Such release may be obtained in different ways.
  • One method is to administer the required amount of PTH intravenously over the appropriate period of time.
  • Another method involves transdermic application, releasing the active ingredient within the desired period of time. This may be effected using a patch which is applied to the skin for the desired period of time. By adding permeation accelerators, release of the active ingredient through the skin as regularly as possible can be ensured so that during appli ⁇ cation of the patch to the skin, continuous release of the active ingredient and permeation through the skin take place.
  • Another way of transdermic application involves ion ⁇ tophoresis. To this end. an appropriate dosage unit (iontophoretic patch) is applied to the skin, and release of the active ingredient through the skin within the desired period of time is controlled by applying an electrical potential.
  • loaded liposomes Preferably, loaded liposomes.
  • PTH or a PTH fragment may be administered in the form of a continuous infusion preferably over two to six hours, particularly about four hours.
  • a tendency to higher anabolic activity can be observed following an infusion of about four hours compared to a one hour infusion or subcutaneous bolus administration.
  • An exceedingly good osteogenous activity was observed following a four hour intravenous infusion of hPTH(l-34) on five working days within two successive weeks.
  • water is used as injection medium, containing additives common with injection solutions, such as stabilizers, solubilizers and buffers.
  • additives are. e.g., tartrate and citrate buffers, ethanol, complexing agents such as ethylenediaminetetra- acetic acid and non-toxic salts thereof, high molecular weight polymers such as liquid poly(ethylene oxide) for viscosity control.
  • Liquid carrier substances must be sterile and are preferably filled into ampoules.
  • the dosage may depend on various factors such as mode of application, species, age or individual condition. Usually, from 30 to 50 ⁇ g/kg/day are administered.
  • the invention relates to the use of parathyroid hormone or a parathyroid hormone derivative in the treatment of osteoporosis by application in the form of a continuous infusion for two to six hours or a transdermic or enteric administration form having an active ingredient release period of from two to six hours.
  • Such examinations relating to the use of PTH or PTH fragments, according to the invention will be subject to protection, particularly within the scope of clinical tests for the purpose of authorization according to the drug law.
  • the corresponding petitioned authorization according to the drug law relates to the treatment of calcium-metabolic dis ⁇ eases in general and to the treatment of osteoporosis, in particular.
  • the invention is directed to a method for osteoporosis treatment of the human body wherein, in order to increase the bone matter, a therapeutically effective amount of parathyroid hormone or parathyroid hormone derivative is applied in the form of a continuous infusion for two to six hours or a transdermic or enteric administration form having an active ingredient release period of from two to six hours.
  • a therapeutically effective amount of parathyroid hormone or parathyroid hormone derivative is applied in the form of a continuous infusion for two to six hours or a transdermic or enteric administration form having an active ingredient release period of from two to six hours.
  • the method according to the invention is conducted within the scope of clinical tests for the purpose of authorization according to the drug law.
  • a venous permanent catheter was implanted in male Wistar rats weighing about 230-250 g.
  • the animals were assigned to 5 different groups of treatment of 6 animals each, which were treated as follows:
  • the compa- rison comprises intravenous infusion of 40 ⁇ g/kg and 80 ⁇ g/kg over four and eight hours, respectively, as well as subcutaneous injection of 40 ⁇ g/kg and intravenous bolus injection of 80 ⁇ g/kg.
  • Group 1 4 hours iv; 40 ⁇ g/kg/day
  • Group 2 8 hours iv; 80 ⁇ g/kg/day
  • a pilot experiment on transdermic application by iontophoresis was conducted on two rabbits. The animals were trimmed in the flanks, and the skin was cleaned with ethanol. A filter paper soaked with hPTH(l-34) solution was placed on the skin and fixated with a chlorinated silver electrode. Iontophoresis was carried out over a time period of 90 and 105 minutes, respectively, under the following conditions: current intensity: 5-7 mA, current density: 0.44-0.62 mA/cm , current pulses: 8 ms at 2 ms intervals. During the experiment, blood was taken from the ear artery at various times (see table below), and the serum obtained was deep frozen. Using the Nichols RIA INS-PTH, the PTH concentration in the serum samples was measured. Result: In both animals, a significant level of hPTH(l-34) could be detected after a period of 1 to 1.5 hours.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to a pharmaceutical administration form of parathyroid hormone or parathyroid hormone derivatives having an active ingredient release period of from two to six hours, the use of parathyroid hormone for the preparation of such pharmaceutical administration forms, and to a method for treating osteoporosis in the human body.

Description

Pharmaceutical Administration Form of Parathyroid Hormone
Having an Active Ingredient Release Period of from Two to Six Hours
The present invention is directed to a pharmaceutical administration form of parathyroid hormone or parathyroid hormone derivatives having an active ingredient release period of from two to six hours, the use of parathyroid hormone in the treatment of osteoporosis by applying said pharmaceutical administration form, and a method for the treatment of osteoporosis in the human body.
Parathyroid hormone and N-terminal parathyroid hormone fragments are known to have osteogenous activity which has been observed in animal experimental studies on rats as well as in clinical studies on osteoporotic patients and has been described in technical literature (Selye, Endocrinology 16 (1932), 547-558; Hefti et al., Clin. Sci. 62 (1982), 389-396; Gunnes-Hey et al., Metab. Bone Dis. Relat. Res. 5 (1984), 177-181; Reeve et al., Br. Med. J. 280 (1980), 1340-1344; Slovik et al., J. Bone Miner. Res. 1 (1986), 377- 381, EP 0,197,514).
There is general agreement in the art about the fact that the osteogenous activity of PTH is bound to a pulsatile or intermittent application. Pulsatile application of PTH in animal experimental as well as in clinical studies on patients resulted in an increase of bone matter (Tarn et al., Endocrinology 110(2) (1982), 506-512; Podbesek et al., Endo¬ crinology 112(3) (1983), 1000-1006; Hock et al., J. Bone Miner. Res. 7(1) (1992), 65- 72; Reeve et al., Br. Med. J. 280 (1980), 1340-1344; Slovik et al., J. Bone Miner. Res. 1 (1986), 377-381).
While in animal experiments an increased bone transformation rate was observed with continuous infusion of PTH, this, however, did not result in a net gain of bone matter (Tarn et al.. Endocrinology 110 (2) (1982), 506-512; Malluche et al., Am. J. Physiol. 242(2) (1982), F197-F201; Hock et al.. J. Bone Miner. Res. 7(1) (1992), 65-72; Podbe- sek et al.. Endocrinology 1 12(3) ( 1983), 1000-1006).
Surprisingly, it has now been found that continuous application of PTH or derivatives thereof certainly results in a net gain of bone matter, when limited to up to six hours.
Therefore, the invention is directed to a pharmaceutical administration form of PTH or derivatives thereof having an active ingredient release period of from two to six hours, and preferably of four hours. Here, the pharmaceutical administration form may be an infusion solution or a transdermic or enteric pharmaceutical system having an active ingredient release period of up to six hours. Compared to pulsatile application which in all hitherto known animal experimental and clinical studies has been effected as a daily subcutaneous injection, the transdermic or enteric application of PTH offers the decisive advantage of retarded active ingredient release. Abrupt PTH pulses and the associated substantial disturbance of the patient's well-being due to the necessary injection can be dismissed.
According to the present invention, the pharmaceutical administration form contains biologically active parathyroid hormone or parathyroid hormone derivatives, particularly human PTH(l-84) or an N-terminal human PTH fragment having the sequences 1-29 to
1-41, preferably the sequences 1-34, 1-35, 1-36, 1-37, or 1-38. Furthermore, PTΗ- analogous peptides, variants or modifications of parathyroid hormone (PTH agonists) resulting from the replacement of single or multiple amino acids in the amino acid se¬ quence of unmodified parathyroid hormone may also be employed. In addition, PTH fragments appropriately abridged at the N terminus and/or the C terminus are also possible within the meaning of the invention. Such fragments have been described in WO 90/10067, EP 0,301,484 or EP 0,301,485, for example.
Application of the PTH peptides is effected in such a manner that release of the pharmacologically active substance in the body within a period of from 2 to 6 hours is ensured. Such release may be obtained in different ways. One method is to administer the required amount of PTH intravenously over the appropriate period of time. Another method involves transdermic application, releasing the active ingredient within the desired period of time. This may be effected using a patch which is applied to the skin for the desired period of time. By adding permeation accelerators, release of the active ingredient through the skin as regularly as possible can be ensured so that during appli¬ cation of the patch to the skin, continuous release of the active ingredient and permeation through the skin take place. Another way of transdermic application involves ion¬ tophoresis. To this end. an appropriate dosage unit (iontophoretic patch) is applied to the skin, and release of the active ingredient through the skin within the desired period of time is controlled by applying an electrical potential.
Preferably, loaded liposomes. microspheres made of common polymers, or proteinoid complexes ensuring resorption of the active ingredient in the small intestine over an ap¬ propriate period of time are possible as enteric pharmaceutical systems.
According to the invention, PTH or a PTH fragment may be administered in the form of a continuous infusion preferably over two to six hours, particularly about four hours. Here, a tendency to higher anabolic activity can be observed following an infusion of about four hours compared to a one hour infusion or subcutaneous bolus administration. An exceedingly good osteogenous activity was observed following a four hour intravenous infusion of hPTH(l-34) on five working days within two successive weeks.
Further examinations using PTH(l-37) showed that levels maintained for 8 hours at 80 μg/kg iv, i.e., at the same infusion rate as 40 μg/kg iv over 4 hours, give rise to severe adverse effects on the bones, while at 40 μg/kg PTH(l-37) iv over 4 hours a distinct osteoanabolic effect occurs. In contrast, intravenous bolus injection of 80 μg/kg PTH(l-37) within about one minute does not result in negative but positive effects with respect to the relative X-ray density and the Ca content. However, the therapeutic utility of comparably high intravenous PTH doses in the form of a bolus administration is not deemed advantageous due to severe circulatory effects to be expected. Preferably, water is used as injection medium, containing additives common with injection solutions, such as stabilizers, solubilizers and buffers. Such additives are. e.g., tartrate and citrate buffers, ethanol, complexing agents such as ethylenediaminetetra- acetic acid and non-toxic salts thereof, high molecular weight polymers such as liquid poly(ethylene oxide) for viscosity control. Liquid carrier substances must be sterile and are preferably filled into ampoules.
The dosage may depend on various factors such as mode of application, species, age or individual condition. Usually, from 30 to 50 μg/kg/day are administered.
In addition, the invention relates to the use of parathyroid hormone or a parathyroid hormone derivative in the treatment of osteoporosis by application in the form of a continuous infusion for two to six hours or a transdermic or enteric administration form having an active ingredient release period of from two to six hours. Such examinations relating to the use of PTH or PTH fragments, according to the invention, will be subject to protection, particularly within the scope of clinical tests for the purpose of authorization according to the drug law. As a rule, the corresponding petitioned authorization according to the drug law relates to the treatment of calcium-metabolic dis¬ eases in general and to the treatment of osteoporosis, in particular.
Likewise, the invention is directed to a method for osteoporosis treatment of the human body wherein, in order to increase the bone matter, a therapeutically effective amount of parathyroid hormone or parathyroid hormone derivative is applied in the form of a continuous infusion for two to six hours or a transdermic or enteric administration form having an active ingredient release period of from two to six hours. Preferably, the method according to the invention is conducted within the scope of clinical tests for the purpose of authorization according to the drug law.
In the following, the invention will be illustrated in more detail by way of embodiments. Example 1
Infusion of PTH for various periods of time
In a pre-operation, a venous permanent catheter was implanted in male Wistar rats weighing about 230-250 g. The animals were assigned to 5 different groups of treatment of 6 animals each, which were treated as follows:
1. Rinsing the catheter with solvent on 5 working days within two successive weeks = negative control.
2. Intravenous infusion of hPTH(l-34), 40 μg/kg/day within one hour on 5 working days within two successive weeks.
3. Intravenous infusion of hPTH(l-34), 40 μg/kg/day within four hours on 5 working days within two successive weeks.
4. Intravenous infusion of hPTH(l-34), 40 μg/kg/day within eight hours on 5 working days within two successive weeks.
5. Subcutaneous bolus injection of hPTH(l-34), 40 μg/kg/day on 5 working days within two successive weeks = positive control.
6. In another experiment, PTH(l-37) was tested under various conditions. The compa- rison comprises intravenous infusion of 40 μg/kg and 80 μg/kg over four and eight hours, respectively, as well as subcutaneous injection of 40 μg/kg and intravenous bolus injection of 80 μg/kg.
On the third day following the last treatment, the animals were sacrificed and the femora were removed for subsequent analysis of femur weight, volume, dry weight, ash weight, and calcium content. The results for PTHd-34) are summarized in the following Table 1. showing that a significant increase of bone matter was observed in the Treatment Groups 1 (1 hour infu¬ sion), 2 (4 hours infusion) and 4 (sc bolus), while no differences compared to the control group occurred in Group 3 (8 hours infusion).
Table 1
Continuous infusion of PTH(l-34) on rats (Wistar) Duration of treatment: Continuous infusion for 1 hour (Group 1), 4 hours (Group 2), 8 hours (Group 3) once per day iv, and once per day subcutaneous (sc) (Group 4). Dose: 40 μg PTH(l-34)/kg/day n = 5 - 6
Group 1 Group 2 Group 3 Group 4
Duration of infusion Control 1 hour iv 4 hours iv 8 hours iv sc
Lene h (mm)
Median 34 34 34 34 34
1st quart. 34 34 34 33 34
3rd quart. 34 35 34 34 34
Volume (μl)
Median 645 648 672 680 639
1st quart. 628 639 645 642 627
3rd quart. 675 670 679 683 668
Drv weieht (mg)
Median 458 499 520 471 512
1st quart. 445 479 518 458 493
3rd quart. 473 517 539 503 522
Ash weieht (me)
Median 278 308 328 280 316
1st quart. 270 296 323 278 306
3rd quart. 288 320 337 308 321 Group 1 Group 2 Group 3 Group 4 hour iv 4 hours iv
Duration of infusion Control 1 8 hours iv sc
Ca content (me)
Median 100 1 13 123 102 115
1st quart. 98 109 115 99 115
3rd quart. 106 116 131 112 116
Drv Weieht/Volume
(mg/ml)
Median 707 758 794 710 786
1st quart. 682 747 773 671 776
3rd quart. 715 784 820 740 795
Ash Weieht/Volume
(me/ml)
Median 428 468 497 - 433 488
1st quart. 412 459 481 401 479
3rd quart. 438 485 519 453 490
Ca Content/Volume
(me/ml)
Median 155 171 192 155 175
1st quart. 152 170 171 145 171
3rd quart. 158 176 193 164 180
In one test series of PTH(l-37) the influence of duration at an identical infusion rate (40 μg/kg iv over four hours; 80 μg/kg iv over eight hours) was examined. Here, it appeared that a significant osteoanabohc effect occurred at 40 μg/kg PTΗ(l-37) iv over four hours, while the double infusion time period of eight hours at an overall amount of 80 μg/kg iv resulted in dramatic negative effects on the bone balance. In contrast, repeated intravenous bolus injection of 80 μg/kg within about one minute had a positive effect on the bone balance. However, the therapeutic utility of comparably high intravenous PTH doses in the form of a bolus administration is not deemed advantageous due to the relatively small effect and, in particular, due to severe circulatory effects to be expected. The results for PTH(l-37) are summarized in Table 2.
Table 2
a) Effect of PTH(l-37) by intravenous infusion on rats Duration of treatment: 10 working days, once per day
Dose: 40 (4 hours) and 80 (8 hours) μg/kg/day, respectively
Infusion rate: 10 μg/kg/hour
Group 1 : 4 hours iv; 40 μg/kg/day
Group 2: 8 hours iv; 80 μg/kg/day
Group 3 : subcutaneous (sc); 40 μg/kg/day n = 7 - 10
Group 1 Group 2 Group 3
Duration of infusion Control 4 hours iv 8 hours iv sc
Relative X-Rav Densitv (mmAI)
Median 1.5 2.0 1.5 1.8
1st quart. 1.3 2.0 1.3 1.7
3rd quart. 1.6 2.2 1.7 1.8
Lenεth (mm)
Median 36 35 34 36
1st quart. 35 35 34 36
3rd quart. 36 36 35 36
Volume (ul)
Median 709 786 737 775
1st quart. 659 752 692 710
3rd quart. 735 803 831 814 Group 1 Group 2 Group 3
Control 4 hours iv 8 hours iv
Duration of infusion sc
Drv Weieht (me)
Median 515 600 424 599
1st quart. 476 581 420 570
3rd quart. 535 608 500 633
Ash Weieht (me)
Median 329 381 262 384
1st quart. 308 377 256 357
3rd quart. 336 388 330 398
Ca Content (me)
Median 119 138 95 140
1st quart. 111 137 93 132
3rd quart. 120 140 1 19 145
Drv Weieht/Volume (me/ml)
Median 716 770 593 768
1st quart. 709 756 533 743
3rd quart. 736 785 618 779
Ash Weieht Volume (me/ml)
Median 460 490 356 484
1st quart. 450 480 319 467
3rd quart. 474 506 384 487
Ca Content/Volume (me/ml)
Median 167 177 134 177
1st quart. 164 174 116 170
3rd quart. 172 181 158 179 b) Effect of PTH( 1 -37) by intravenous bolus administration on rats Duration of treatment: 10 working days, once per day
Dose: 80 μg/kg/day
Infusion rate: 10 μg 'kg/hour
Group 4: intravenous bolus administration n = 7 - 10
Group 4
Control Bolus iv
Relative X-Rav Densitv (mmAI)
Median 1.0 1.3
1st quart. 0.9 1.2
3rd quart. 1.0 1.3
Leneth (mm)
Median 35 35
1st quart. 35 34
3rd quart. 35 36
Volume (ul)
Median 562 635
1st quart. 522 624
3rd quart. 641 714
Drv Weieht (me)
Median 449 517
1st quart. 426 487
3rd quart. 466 548
Ash Weieht (me)
Median 299 348
1st quart. 293 329
3rd quart. 313 366
Ca Content (me)
Median 102 119
1st quart. 101 114
3rd quart. 106 126 Group 4
Control Bolus iv
Drv Weieht/Volume (me/ml)
Median 771 800
1st quart. 726 754
3rd quart. 817 829
Ash Weieht/Volume (me/ml)
Median 513 527
1st quart. 483 507
3rd quart. 561 549
Ca Content Volume (me/ml)
Median 175 182
1st quart. 165 176
3rd quart. 191 189
Example 2
Iontophoretic application of PTH
A pilot experiment on transdermic application by iontophoresis was conducted on two rabbits. The animals were trimmed in the flanks, and the skin was cleaned with ethanol. A filter paper soaked with hPTH(l-34) solution was placed on the skin and fixated with a chlorinated silver electrode. Iontophoresis was carried out over a time period of 90 and 105 minutes, respectively, under the following conditions: current intensity: 5-7 mA, current density: 0.44-0.62 mA/cm , current pulses: 8 ms at 2 ms intervals. During the experiment, blood was taken from the ear artery at various times (see table below), and the serum obtained was deep frozen. Using the Nichols RIA INS-PTH, the PTH concentration in the serum samples was measured. Result: In both animals, a significant level of hPTH(l-34) could be detected after a period of 1 to 1.5 hours.
hPTH(l-34) [pg/ml]
Time [min]
0 20 30 45 60 90 105 120
Animal 1 36 112 123 1834
Animal 2 52 107 112 391 915 1420 1315

Claims

C L A I M S :
1. A pharmaceutical administration form, containing parathyroid hormone (PTH) or a parathyroid hormone derivative as the active ingredient, with an active ingredient release period of from two to six hours.
2 The administration form according to claim 1, comprising an infusion solution for continuous infusion of from two to six hours and preferably, four hours.
3. The administration form according to claim 1, comprising a transdermic pharmaceu¬ tical system, preferably a patch or an iontophoretic system.
4. The administration form according to claim 1, comprising an enteric pharmaceutical system, preferably loaded liposomes. or microspheres made of common polymers, or proteinoid complexes.
5. The administration form according to one of claims 1 to 4, containing human PTH(l-84).
6. The administration form according to one of claims 1 to 4. containing the N-terminal fragments of human PTH comprising the sequences 1-29 through 1-41, preferably 1-34, 1-35, 1-36, 1-37, and 1-38.
7. Use of parathyroid hormone or parathyroid hormone derivatives for the preparation of an administration form having an active ingredient release period of from two to six hours.
8. The use according to claim 7 for the preparation of an infusion solution for continuous infusion of from two to six hours and preferably, four hours.
9. The use according to claim 7 for the preparation of a transdermic or enteric administration form.
10. A method for osteoporosis treatment of the human body wherein, in order to increase the bone matter, a therapeutically effective amount of parathyroid hormone or parathyroid hormone derivative is applied in the form of a continuous infusion for two to six hours or a transdermic or enteric administration form having an active ingredient release period of from two to six hours.
1 1. The method according to claim 10, conducted within the scope of clinical tests for the purpose of authorization according to the drug law.
12. The method according to claim 10 or 1 1, wherein from 30 to 50 μg/kg/day parathy¬ roid hormone or parathyroid hormone derivative is used as therapeutically effective amount.
13. The method according to one of claims 10 to 12, wherein said continuous infusion is effected on 5 working days within two successive weeks.
14. The method according to one of claims 10 to 12, wherein said transdermic applica¬ tion is effected using a patch optionally containing permeation accelerators, or by iontophoresis.
15. The method according to one of claims 10 to 12, wherein said enteric application is effected using loaded liposomes, microspheres made of common polymers, or pro- teinoid complexes.
PCT/EP1996/001962 1995-05-12 1996-05-09 Pharmaceutical administration form of parathyroid hormone having an active ingredient release period of from two to six hours WO1996035447A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP96919738A EP0825872A1 (en) 1995-05-12 1996-05-09 Pharmaceutical administration form of parathyroid hormone having an active ingredient release period of from two to six hours
AU58165/96A AU5816596A (en) 1995-05-12 1996-05-09 Pharmaceutical administration form of parathyroid hormone ha ving an active ingredient release period of from two to six hours
JP8533762A JPH11505222A (en) 1995-05-12 1996-05-09 Pharmaceutical dosage form of parathyroid hormone with active ingredient release period of 2 to 6 hours

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19517430A DE19517430A1 (en) 1995-05-12 1995-05-12 Pharmaceutical dosage form of parathyroid hormone with a two to six hour drug release period
DE19517430.5 1995-05-12

Publications (1)

Publication Number Publication Date
WO1996035447A1 true WO1996035447A1 (en) 1996-11-14

Family

ID=7761731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/001962 WO1996035447A1 (en) 1995-05-12 1996-05-09 Pharmaceutical administration form of parathyroid hormone having an active ingredient release period of from two to six hours

Country Status (7)

Country Link
EP (1) EP0825872A1 (en)
JP (1) JPH11505222A (en)
AU (1) AU5816596A (en)
DE (1) DE19517430A1 (en)
IL (1) IL118202A0 (en)
WO (1) WO1996035447A1 (en)
ZA (1) ZA963714B (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0922467A2 (en) 1997-12-12 1999-06-16 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
US7994129B2 (en) 2005-11-10 2011-08-09 Michigan Technological University Methods of using black bear parathyroid hormone
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9555014B2 (en) 2010-05-12 2017-01-31 Radius Health, Inc. Therapeutic regimens
US9920044B2 (en) 2010-09-28 2018-03-20 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
US10385008B2 (en) 2017-01-05 2019-08-20 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCL
US11413258B2 (en) 2015-04-29 2022-08-16 Radius Pharmaceuticals, Inc. Methods for treating cancer
US11643385B2 (en) 2018-07-04 2023-05-09 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCl
US11771682B2 (en) 2016-06-22 2023-10-03 Ellipses Pharma Ltd. AR+ breast cancer treatment methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987000750A1 (en) * 1985-08-01 1987-02-12 The Regents Of The University Of California A method and composition for regulating serum calcium levels of mammals
WO1991006564A1 (en) * 1989-10-27 1991-05-16 Forssmann Wolf Georg hPTH (1-37) FRAGMENT, ITS PRODUCTION, DRUG CONTAINING IT AND ITS USE
EP0643981A1 (en) * 1993-09-22 1995-03-22 Takeda Chemical Industries, Ltd. A matrix for iontophoreses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987000750A1 (en) * 1985-08-01 1987-02-12 The Regents Of The University Of California A method and composition for regulating serum calcium levels of mammals
WO1991006564A1 (en) * 1989-10-27 1991-05-16 Forssmann Wolf Georg hPTH (1-37) FRAGMENT, ITS PRODUCTION, DRUG CONTAINING IT AND ITS USE
EP0643981A1 (en) * 1993-09-22 1995-03-22 Takeda Chemical Industries, Ltd. A matrix for iontophoreses

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0922467A2 (en) 1997-12-12 1999-06-16 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
EP0922467A3 (en) * 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
US6526316B2 (en) 1997-12-12 2003-02-25 Hisamitsu Pharmaceutical Co., Inc. Iontophoresis method
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
US7994129B2 (en) 2005-11-10 2011-08-09 Michigan Technological University Methods of using black bear parathyroid hormone
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9555014B2 (en) 2010-05-12 2017-01-31 Radius Health, Inc. Therapeutic regimens
US9920044B2 (en) 2010-09-28 2018-03-20 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
US11413258B2 (en) 2015-04-29 2022-08-16 Radius Pharmaceuticals, Inc. Methods for treating cancer
US11819480B2 (en) 2015-04-29 2023-11-21 Radius Pharmaceuticals, Inc. Methods for treating cancer
US11771682B2 (en) 2016-06-22 2023-10-03 Ellipses Pharma Ltd. AR+ breast cancer treatment methods
US10385008B2 (en) 2017-01-05 2019-08-20 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCL
US11708318B2 (en) 2017-01-05 2023-07-25 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCL
US11643385B2 (en) 2018-07-04 2023-05-09 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCl

Also Published As

Publication number Publication date
JPH11505222A (en) 1999-05-18
ZA963714B (en) 1997-11-10
AU5816596A (en) 1996-11-29
EP0825872A1 (en) 1998-03-04
DE19517430A1 (en) 1996-11-14
IL118202A0 (en) 1996-09-12

Similar Documents

Publication Publication Date Title
RU2155042C2 (en) Parathormone and raloxifen used for bone mass increase, pharmaceutical composition and method of osseous mass increase
EP0559751B1 (en) Treatment for osteoporosis using growth hormone release factor (grf) in combination with parathyroid hormone (pth)
Eaves et al. Effects of corticotropin releasing factor on locomotor activity in hypophysectomized rats
EP0233901B1 (en) A method and composition for regulating serum calcium levels of mammals
PH26085A (en) Method for preventing secondary effects of hyperinsulinemia
US20100221274A1 (en) Method of administering a thymosin alpha 1 peptide
WO1996035447A1 (en) Pharmaceutical administration form of parathyroid hormone having an active ingredient release period of from two to six hours
JP2008516994A (en) Growth hormone secretagogue and use thereof
US6623732B1 (en) Pharmaceutical formulation for nasal administration
US4870054A (en) Treatment for osteoporosis using GRF or a biologically active analog thereof
US4710382A (en) Treatment for osteoporosis using hGRF(1-40)NH2
CN1822850A (en) Treatment or prevention of damage due to radiation exposure.
US5830857A (en) Method of treating epilepsy
JP2012517483A (en) Compositions and methods for minimally invasive systemic delivery of TGF-β superfamily member-containing proteins
EP2067482A1 (en) Agent for preventing development of reflex sympathetic dystrophy after stroke
EP4340865A1 (en) Use of erythropoietin (epo) or erythropoiesis-stimulating agent (esa) to treat osteomyelitis, bone infection, and bone inflammation
JPH07101877A (en) Pharmaceutical agent for thrombocytopenia
WO2019160910A1 (en) Fibroblast growth factor analogs and uses thereof
Recker et al. Treatment for osteoporosis using hGRF (1-40) NH 2
Vance et al. Sandostatin®(SMS 201–995) in the Treatment of Acromegaly
Kitamura et al. Biochemistry of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP)
Amano et al. Filter leukapheresis—The new promising therapeutic approach for inflammatory bowel disease
CN1204263A (en) Method for effecting changes in central nervous system by administration of IGF-I or IGF-II
JPH07316071A (en) Therapeutic agent for muscular dystrophy
AU2008200190A1 (en) Method of Administering a Thymosin Alpha 1 Peptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 533762

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 945801

Date of ref document: 19971110

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996919738

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996919738

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1996919738

Country of ref document: EP